Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Combination sunscreen active ingredients **padimate o** (a UVB-absorbing ester derivative of PABA) and **oxybenzone** (a broad-spectrum benzophenone filter) have historically been used together to provide moderate SPF and extended protection against UVB and some UVA rays. Padimate o is a potent UVB absorber but offers little to no UVA protection; oxybenzone absorbs UVB and short-wave UVA, widening the spectrum of coverage[1][2][3][9][10]. The combination mechanism relies on both agents' ability to absorb solar UV radiation upon topical application, protecting skin from direct DNA damage, sunburn, premature aging, and skin cancer. However, padimate o is largely discontinued due to safety issues, including allergic reactions, DNA damage, potential carcinogenicity, and severe cosmetic staining[1][2][3][4]; while oxybenzone remains in some sunscreens but is controversial due to endocrine disruption and environmental impact concerns the combination is rarely found in modern products[3][4]. The combination's developers were various sunscreen manufacturers, but current production is nearly obsolete and discouraged due to documented safety risks[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on padimate o + oxybenzone (Coppertone).